FATE - Fate Therapeutics GAAP EPS of -$0.19 beats by $0.47 revenue of $58.98M beats by $25.45M May, 03 2023 04:05 PM Fate Therapeutics Inc. 2023-05-03 16:05:12 ET Fate Therapeutics press release ( NASDAQ: FATE ): Q1 GAAP EPS of -$0.19 beats by $0.47 . Revenue of $58.98M (+220.5% Y/Y) beats by $25.45M . For further details see: Fate Therapeutics GAAP EPS of -$0.19 beats by $0.47, revenue of $58.98M beats by $25.45M